ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 596 for:    "lipid metabolism, inborn errors" OR "farber lipogranulomatosis"

Sitosterolemia Metabolism (STAIR7002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01584206
Recruitment Status : Unknown
Verified December 2015 by University of Manitoba.
Recruitment status was:  Active, not recruiting
First Posted : April 24, 2012
Last Update Posted : March 10, 2016
Sponsor:
Information provided by (Responsible Party):
University of Manitoba

Brief Summary:
Ezetimibe has become the treatment choice for patients with sitosterolemia. Ezetimibe is an inhibitor of cholesterol absorption from the gastrointestinal tract. The purpose of this study is to determine if ezetimibe improves whole body plant sterol and cholesterol homeostasis.

Condition or disease Intervention/treatment Phase
Sitosterolemia Drug: Ezetimibe Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe
Study Start Date : April 2012
Actual Primary Completion Date : August 2013
Estimated Study Completion Date : December 2016


Arm Intervention/treatment
Experimental: Ezetimibe
Compare on and off ezetimibe
Drug: Ezetimibe
10mg ezetimibe/day, at least 4 months




Primary Outcome Measures :
  1. Plasma cholesterol level [ Time Frame: 8 months ]
    Plasma cholesterol level will be assessed by GC

  2. Plasma sitosterol level [ Time Frame: 8 months ]
    Plasma plant sterol assessment using GC


Secondary Outcome Measures :
  1. Cholesterol absorption [ Time Frame: 4 month ]
    Use stable isotope technique to assess cholesterol absorption

  2. Cholesterol synthesis [ Time Frame: 4 months ]
    Use of stable isotope to assess cholesterol synthesis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • confirmed diagnosis of homozygous sitosterolemia as established by genotyping and clinical parameters

Exclusion Criteria:

  • pregnant
  • intellectual disability
  • major infectious diseases
  • immunodeficiency
  • cancer
  • renal failure
  • diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01584206


Locations
Canada, Manitoba
Richardson Centre for Functional Foods and Nutraceuticals
Winnipeg, Manitoba, Canada, R3T 2N2
Sponsors and Collaborators
University of Manitoba
Investigators
Principal Investigator: Semone B Myrie, PhD University of Manitoba
Study Chair: Peter J Jones, PhD University of Manitoba

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Manitoba
ClinicalTrials.gov Identifier: NCT01584206     History of Changes
Other Study ID Numbers: B2011:051
First Posted: April 24, 2012    Key Record Dates
Last Update Posted: March 10, 2016
Last Verified: December 2015

Keywords provided by University of Manitoba:
Sitosterolemia
Ezetimibe
Plant sterol
Cholesterol

Additional relevant MeSH terms:
Lipid Metabolism, Inborn Errors
Hypercholesterolemia
Intestinal Diseases
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Ezetimibe
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents